This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Tsumura & Co. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024 CI
Tsumura & Co. Announces Dividend for the second quarter ended September 30, 2023, Payable on December 5, 2023 and Provides Dividend Guidance for the Full Year Ending March 31, 2024 CI
Tsumura & Co. Provides Consolidated Earnings Guidance for the First Half Ending September 30, 2023 and Full Year Ending March 31, 2024 CI
Tsumura & Co. Provides Dividend Guidance for the End of Second Quarter and Full Year Ending March 31, 2024 CI
Tsumura's Fiscal 2023 Profit Falls 12.5%; Shares Slip 4% MT
Tsumura & Co. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Tsumura & Co. Provides Consolidated Financial Guidance for the First Half and Full Year Ending March 31, 2024 CI
Tsumura & Co. Announces Year End Dividend for the Fiscal Year Ended March 31, 2023, and Provides Second Quarter and Year End Dividend Forecast for the Fiscal Year Ending March 31, 2024 CI
Kontafarma China Unit to Sell 66% Equity Interest of Shaanxi Unisplendour for 168.2 Million Yuan; Shares Slip 7% MT
Robit, Inc. announced that it has received ¥499 million in funding from Tsumura & Co. CI
Tsumura & Co. Provides Dividend Guidance for the Full Year Ending March 31, 2023 CI
Tsumura & Co. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023 CI
Tsumura & Co. Announces Dividend for the Period Ended September 30, 2022, Payable on December 5, 2022 and Provides Dividend Guidance for the Full Year Ending March 31, 2023 CI
Tsumura & Co. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023 CI
Tsumura & Co. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023 CI
Tsumura & Co. Provides Consolidated Earnings Guidance for the First Half and Fiscal Year Ending March 31, 2023 CI
Tsumura & Co. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023 CI
Tsumura & Co. Provides Consolidated Earnings Guidance for the First Half and Fiscal Year Ending March 31, 2023 CI
Tsumura & Co. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2022 CI
Tsumura & Co. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2022 CI
Tsumura & Co. Provides Earnings Guidance for the Year Ending March 31, 2022 CI
Tsumura & Co. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2022 CI
Tsumura & Co's Attributable Profit Climbs 34% in Fiscal Q1 MT
Tsumura & Co. Announces Consolidated Earnings Results for the First Quarter of Year Ending March 31, 2022 CI
Tsumura & Co. Provides Earning Provides Earnings Forecast for the First Half and Full Year of Year Ending March 31, 2022 CI
Chart Tsumura & Co.
More charts
TSUMURA & CO. is a Japan-based company mainly engaged in the manufacture and sale of ethical and general pharmaceuticals. Through its subsidiaries, the Company is also engaged in the procurement, sorting and processing of crude drugs, the manufacture and sale of Chinese herbal extract powders and drug substances, the operation of dispensing pharmacies and the provision of logistics services, as well as the development of pharmaceuticals.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3,755 JPY
Average target price
4,920 JPY
Spread / Average Target
+31.03%
Consensus
  1. Stock Market
  2. Equities
  3. 4540 Stock
  4. News Tsumura & Co.
  5. Tsumura's Fiscal 2023 Profit Falls 12.5%; Shares Slip 4%